You are here: Industry Insights > NSCLC

News List

LORBRENA significantly improves progression-free survival in first-line ALK-positive lung cancer pharmaceutical-business-review
August 11, 2020
Pfizer announced that the Phase 3 CROWN study of LORBRENA (lorlatinib) in people with previously untreated advanced anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) met its primary endpoint by demonstrating significantly ...
Daiichi Sankyo, AstraZeneca collaborate to evaluate patritumab deruxtecan in combination with TAGRISSO in EGFR-mutated NSCLC pharmaceutical-business-review
August 11, 2020
Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) announced that it has entered into a clinical trial collaboration with AstraZeneca (LSE/STO/NYSE: AZN) to evaluate the combination of patritumab deruxtecan (U3-1402) ...
PharmAbcine, SLBio Enter NSCLC Research Pact contractpharma
August 04, 2020
To evaluate olinvacimab and C-005, a 3rd generation of EGFR inhibitor with superior brain-blood-barrier permeability in treating non-small cell lung cancer.
Rozlytrek from Roche gets EC approval to treat solid tumours and NSCLC expresspharma
August 04, 2020
The approval is based on results from the integrated analysis of the pivotal phase II STARTRK-2, phase I STARTRK-1 and phase I ALKA-372-001 trials, and data from the phase I/II STARTRK-NG study.
Thermo Fisher, Chugai Pharmaceutical Enter Companion Diagnostic Agreement americanpharmaceuticalreview
July 17, 2020
Thermo Fisher Scientific has signed a companion diagnostic (CDx) agreement with Chugai Pharmaceutical, a member of the Roche Group, and has applied to the Ministry of Health, Labour and Welfare (MHLW) to expand the use of the Oncomine Dx Target Test in...
Thermo Fisher, Daiichi Sankyo to Co-Develop CDx contractpharma
June 24, 2020
Agreement aims to identify HER2 gene mutations using Oncomine Dx Target Test for patients with Non-Small Cell Lung Cancer.
NICE recommends Rozlytrek (entrectinib) as treatment for NSCLC europeanpharmaceuticalreview
June 17, 2020
After three clinical trials showing its efficacy, NICE has recommended Rozlytrek (entrectinib) as treatment for non-small cell lung cancer (NSCLC).
NICE backs Rozlytrek for subset of NSCLC patients pharmatimes
June 16, 2020
NICE has published final draft guidance backing NHS use of Roche's Rozlytrek (entrectinib) as a treatment option for ROS1-positive, advanced non-small cell lung cancer (NSCLC) not previously treated with ROS1 inhibitors.
FDA Approves Nivolumab plus Ipilimumab, Chemotherapy for Metastatic NSCLC americanpharmaceuticalreview
June 03, 2020
The Food and Drug Administration (FDA) approved the combination of nivolumab (OPDIVO, Bristol-Myers Squibb) plus ipilimumab (YERVOY, Bristol-Myers Squibb) ...
FDA Approves Brigatinib for ALK-Positive Metastatic NSCLC americanpharmaceuticalreview
June 02, 2020
The Food and Drug Administration (FDA) approved brigatinib (ALUNBRIG, ARIAD) for adult patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) as detected by an FDA-approved test.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 20 21 Next page